Business Context and Reporting Period
This Form 8-K Current Report is filed by DarioHealth Corp. (DRIO) on August 20, 2026. The filing addresses Item 5.02 regarding the departure of a senior officer and the execution of related separation and consulting agreements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Departure
The primary material event is the separation of Steven Nelson, President and Chief Commercial Officer.
- Background: Mr. Nelson was on temporary medical leave starting July 10, 2026, which was extended indefinitely.
- Separation Agreement:
- Effective Date: Employment terminates September 30, 2026.
- Role Cessation: He ceases to serve as President and Chief Commercial Officer effective September 1, 2026.
- Compensation: Includes earned wages, accrued vacation, and health insurance through September 30, 2026.
- COBRA Reimbursement: Up to three months of health coverage at $2,600 per month post-separation.
- Equity: Unvested equity awards expire upon termination.
- Consulting Agreement:
- Effective Date: October 1, 2026, through December 31, 2027.
- Services: Advisory calls, industry insights, and strategic introductions.
- Equity Grant: 30,000 shares of restricted common stock (subject to Compensation Committee approval).
- Vesting: Vests on the first anniversary of the grant date or upon a Change in Control.
- Acceleration: If the Company terminates the agreement, 15,000 shares vest immediately.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed relates to the transition of the Chief Commercial Officer role and the associated compensation obligations.
Investor Verification Checklist
- Verify the approval status of the 30,000 restricted stock grant by the Compensation Committee.
- Review the full text of the Separation Agreement (Exhibit 10.1) and Consulting Agreement (Exhibit 10.2) for omitted material terms.
- Monitor the Company's announcement regarding the interim or permanent replacement for the President and Chief Commercial Officer roles.
- Assess the impact of the executive departure on the Company's commercial strategy and sales pipeline.